Advanced search
Publication Cover
Immunological Medicine Volume 45, 2022 - Issue 4
Submit an article Journal homepage
1,258
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis

Kazuyuki Tsuboia Division of Allergology and Rheumatology, Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, JapanORCID Iconhttps://orcid.org/0000-0002-5198-1019
ORCID Icon,
Kazuteru Noguchia Division of Allergology and Rheumatology, Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
,
Masayasu Kitanob Division of Rheumatology, Department of Internal Medicine, Sumitomo Hospital, Nakanoshima, Japan
,
Tetsuya Furukawaa Division of Allergology and Rheumatology, Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
,
Teppei Hashimotoa Division of Allergology and Rheumatology, Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan
,
Naoto Azumaa Division of Allergology and Rheumatology, Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, JapanORCID Iconhttps://orcid.org/0000-0002-4773-1535
ORCID Icon &
Kiyoshi Matsuia Division of Allergology and Rheumatology, Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, JapanCorrespondence[email protected]
 show all
Pages 238-243 | Received 09 Mar 2022, Accepted 21 Jun 2022, Published online: 08 Jul 2022

References

  • Nakazawa D, Masuda S, Tomaru U, et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol. 2019;15(2):91–101.
  • Sada KE, Yamamura M, Harigai M, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16(2):R101.
  • Furuta S, Chaudhry AN, Arimura Y, et al. Comparison of the phenotype and outcome of granulomatosis with polyangiitis between UK and Japanese cohorts. J Rheumatol. 2017;44(2):216–222.
  • Nagasaka K, Harigai M, Hagino N, et al. Systematic review and meta-analysis for 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol. 2019;29(1):119–129.
  • Takakuwa Y, Hanaoka H, Kiyokawa T, et al. Low-dose rituximab as induction therapy for ANCA-associated vasculitis. Clin Rheumatol. 2019;38(4):1217–1223.
  • Tsukamoto H. BAFF and APRIL in systemic lupus erythematosus. Clin Rheumatol. 2015;27:72–75.
  • Sakai J, Akkoyunlu M. The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev. 2017;30(4):991–1014.
  • Matsushita T, Sato S. The role of BAFF in autoimmune diseases. Nihon Rinsho Meneki Gakkai Kaishi. 2005;28(5):333–342.
  • Phatak S, Chaurasia S, Mishra SK, et al. Urinary B cell activating factor (BAFF) and a proliferation‐inducing ligand (APRIL): potential biomarkers of active lupus nephritis. Clin Exp Immunol. 2017;187(3):376–382.
  • Holden NJ, Williams JM, Morgan MD, et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis. 2011;70(12):2229–2233.
  • Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun. 2005;25(4):298–302.
  • Benedetti L, Zardini E, Briani C, et al. B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy. J Neurol Neurosurg Psychiatry. 2011;82(11):1291–1294.
  • Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology. 2019;58(6):1075–1085.
  • van Dam LS, Oskam JM, Kamerling SWA, et al. Highly sensitive flow cytometric detection of residual B-cells after rituximab in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients. Front Immunol. 2020;11(566732):566732.
  • Kitagori K, Kawabata D. B cell abnormality in systemic lupus erythematosus. Jpn J Clin Immunol. 2012;35(6):495–502.
  • Zhang Y, Li J, Zhang YM, et al. Effect of TACI signaling on humoral immunity and autoimmune diseases. J Immunol Res. 2015;2015:247426.
  • Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005;115(11):3083–3092.
  • Laurent SA, Hoffmann FS, Kuhn PH, et al. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6(1):7333.
  • Nagai M, Hirayama K, Ebihara I, et al. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron Clin Pract. 2011;118(4):c339–45.
  • Jha S, Singh J, Minz RW, et al. Increased gene expression of B cell-activating factor of tumor necrosis factor family, in remitting antineutrophil cytoplasmic antibody-associated vasculitis patients. Int J of Rheum Dis. 2022;25(2):218–227.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.